Our Blog

The FDA approved Dupixent for moderate-to-severe atopic dermatitis

April 14, 2017
  The FDA approved Dupixent On March 28th, the FDA approved Dupixent for moderate-to-severe atopic dermatitis. One of the most highly-anticipated approvals of 2017, Dupixent is the latest output ...
Read More

Why Drug Pricing is in the News Now and What Can Be Done About It?

March 3, 2017
Why drug pricing is in the news now and what can be done about it? From Turing Pharmaceuticals to Mylan, there has been no shortage of news coverage on the high cost of prescription drugs. While polit...
Read More

Key Challenges Facing Obamacare Repeal and Replace Plan

February 3, 2017
ACA repeal and replacement complicated by two key challenges...
Read More

How Pharma Can Prepare for the Patent Cliff

February 2, 2017
Extending market exclusivity and responding properly to the volume of recent patent expiries are critical to the sustainability of pharmaceutical corporations.  In the midst of the 2012-2019 patent c...
Read More

Innovation in Pharma Sees Drop in 2016

January 20, 2017
2016 proved to be less than stellar for pharmaceutical companies for a number of reasons, not least being a low point for marketing approval of new products (22 in 2016). While the industry continues ...
Read More

Vermont Drug Price Transparency Bill

December 14, 2016
Vermont recently became the first state to pass a law requiring pharmaceutical manufacturers to either disclose and explain company rationale for product price increases or face legal consequences. Pe...
Read More

Biking for a World Without Diabetes

December 1, 2016
Every year, our bike-enthusiast team members eagerly await the national American Diabetes Association (ADA) Tour de Cure event. It’s a chance for the team to get some fresh air and exercise while he...
Read More